SAN DIEGO--(BUSINESS WIRE)--Speid & Associates announces that the Drug Development Boot Camp will take place at The Harvard Club at 374 Commonwealth Avenue, Boston, in November 2012.
There has never been a greater need for new and innovative treatments for rare diseases, and unmet medical needs. The pharma and biotech industries must become more adept at discovering, selecting, and expediting the best compounds to patients. For this to happen, a paradigm shift in how drugs are discovered, and developed must take place. However, researchers and drug developers tend to work in silos, resulting in specialization, often to the detriment of an adequate understanding of what is needed to bring new medicines to the marketplace. The industry can only reduce the attrition rate if the level of understanding of the drug development process on a whole, is improved. Consequently, there is a need for specialized training that allows the drug developer to hone their skills in a hands-on manner. The Boot Camp uses a method of drug development training that is intensive, and yet fun.
Dr. Speid, President of Speid & Associates, is the founder and co-chair of the Drug Development Boot Camp. Dr. Speid said: “Speid & Associates is delighted to co-host the Boot Camp with Harvard University OTD. The Boot Camp allows the researcher and drug developer to be completely immersed in a drug development atmosphere with some of the best drug developers in the business. Skills are honed, and confidence is gained to do things differently, and therefore potentially more successfully.“
The Drug Development Boot Camp will take place on Wednesday, November 14, and Thursday, November 15, from 7 a.m. to 6 p.m.
Space is limited. Those interested in registering for the Boot Camp should contact Dr. Speid by email or telephone: 858-793-1295.
About Speid & Associates, Inc.
Speid & Associates, Inc. provides global regulatory affairs and drug development consulting services to the pharma and biotech industries. The goal of the company is to expedite access of patients to novel therapeutics, particularly for rare diseases, orphan indications, and unmet medical needs.
For more information visit: www.drugstomarket.com